NCT04221178: Stopping Maintenance Therapy in People With Multiple Myeloma in MRD-Negative Remission
Updated: Jan 27
NCT04221178: Stopping Maintenance Therapy in People With Multiple Myeloma in MRD-Negative Remission
NCT04221178: Stopping Maintenance Therapy in People With Multiple Myeloma in MRD-Negative Remission
This study will test whether stopping maintenance therapy in people with multiple myeloma in MRD-negative remission has the same effect on disease control as continuing this therapy. The study will look at whether people currently on maintenance therapy can safely stop this treatment and continue with active surveillance instead while keeping their MRD-negative remission status for at least 1 year.
Sponsor
Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier: NCT04221178
Official Title: A Single-Arm, Prospective Study of Maintenance Therapy Cessation for Patients With Multiple Myeloma in Sustained MRD-Negative Remissions
First Posted : January 9, 2020
Click here for details on ClinicalTrials.gov
Other: Cessation of continuous maintenance therapy
- New York: Memorial Sloan-Kettering Cancer Center New York
Location
United States, New Jersey
United States, New York